People

Becky Kaufman specializes in U.S. and international patent law. A partner in our Intellectual Property Counseling practice, Becky represents public and private companies, investors and research organizations, particularly in the life sciences, industrial biotechnology and chemical industries.

With an undergraduate degree in biology and graduate work in molecular biology, Becky represents clients in U.S. and international patent prosecution, adversarial proceedings and transactional due diligence in the biological and chemical fields. She also handles licensing, strategic collaborations and other agreements involving intellectual property, and regularly counsels emerging companies on strategies for developing patent portfolios to protect their commercial products.

Previously, Becky was a principal with Cordova Ventures, an early stage venture capital fund, where she worked with its portfolio companies on patent and business matters. Before that, she was with the Georgia Institute of Technology's Advanced Technology Development Center, where she counseled start-ups on patent and business issues. She was also involved in forming the joint Georgia Tech/Emory University biotechnology incubator, EmTech Bio. Becky is very involved in the life sciences community of the southeastern U.S., twice serving as Chairman of Southeast BIO.

Becky has been recognized as an IP Star by Managing Intellectual Property from 2013 through 2016.

Full Bio

Credentials

B.S., Wake Forest University

J.D., University of Pittsburgh

Georgia

Strategy 300: The World's Leading IP Strategists


Intellectual Asset Management, 2016, 2015

Patent 1000: The World's Leading Patent Professionals


Intellectual Asset Management, 2016, 2015

Matters

Advised Arbor Pharmaceuticals, Inc., as IP counsel in connection with its $476 million acquisition of XenoPort, Inc.

Represents Revivicor, Inc. (a subsidiary of United Therapeutics) in client counseling and development of its patent portfolio relating to genetically modified porcine for xenotransplanation.

Represents Nitto Denko Corporation in U.S. and international prosecution of its enhanced transdermal drug-delivery portfolio.

See more
Icon close

Close

Matters

Advised Arbor Pharmaceuticals, Inc., as IP counsel in connection with its $476 million acquisition of XenoPort, Inc.

Represents Revivicor, Inc. (a subsidiary of United Therapeutics) in client counseling and development of its patent portfolio relating to genetically modified porcine for xenotransplanation.

Represents Nitto Denko Corporation in U.S. and international prosecution of its enhanced transdermal drug-delivery portfolio.

Represents The Coca-Cola Company in development of its patent portfolio relating to sweetness enhancers, natural sweeteners and other flavor ingredients.

Represents Emory University in prosecution of its patent portfolio relating to 2'-Fluoro-nucleosides for treatment of viral diseases.

Represented Arbor Pharmaceuticals, Inc. as IP counsel in connection with KKR's acquisition of a minority interest that valued the company at greater than $1 billion.

Represents Kemira in connection with development of its patent portfolio relating to chemical products for use in oil, gas and mining.

Represents Duke University in U.S. and international prosecution of its patent portfolio relating to nucleic acid aptamers targeting therapeutically important proteins, including coagulation proteins.

Represents The Coca-Cola Company in development of its patent portfolio relating to bio-based plastics, including bio-polyethylene terephthalate, or PET, and polyethylene furanoate, or PEF, including PlantBottle.

Represented Regado Biosciences (Tobira Therapeutics) as IP counsel in multiple transactions, including venture capital financings, geographical-based licensing and its initial public offering.

Represented The Coca-Cola Company in negotiating and drafting licensing, development and commercialization agreements relating to novel sweeteners and bio-plastics.

Represented a privately held ophthalmology company in connection with a partial acquisition by a multi-national ophthalmology company.

Represented Nivalis Therapeutics, Inc., as IP counsel in connection with its initial public offering.

Represents Aceras Bio, a healthcare investment firm, in due diligence directed to formation and funding of life sciences companies.

Represents GeoVax, Inc., in client counseling and development of its patent portfolio relating to vaccines for HIV and other viral disorders.

Represented EndoChoice, a platform GI company, as IP counsel in connection with its initial public offering.

Represented a multinational conglomerate in monetization of a patent portfolio directed to mass spectrometric imaging by MALDI-TOF.

Matters

Advised Arbor Pharmaceuticals, Inc., as IP counsel in connection with its $476 million acquisition of XenoPort, Inc.

Represents Revivicor, Inc. (a subsidiary of United Therapeutics) in client counseling and development of its patent portfolio relating to genetically modified porcine for xenotransplanation.

Represents Nitto Denko Corporation in U.S. and international prosecution of its enhanced transdermal drug-delivery portfolio.

See more
Icon close

Close

Matters

Advised Arbor Pharmaceuticals, Inc., as IP counsel in connection with its $476 million acquisition of XenoPort, Inc.

Represents Revivicor, Inc. (a subsidiary of United Therapeutics) in client counseling and development of its patent portfolio relating to genetically modified porcine for xenotransplanation.

Represents Nitto Denko Corporation in U.S. and international prosecution of its enhanced transdermal drug-delivery portfolio.

Represents The Coca-Cola Company in development of its patent portfolio relating to sweetness enhancers, natural sweeteners and other flavor ingredients.

Represents Emory University in prosecution of its patent portfolio relating to 2'-Fluoro-nucleosides for treatment of viral diseases.

Represented Arbor Pharmaceuticals, Inc. as IP counsel in connection with KKR's acquisition of a minority interest that valued the company at greater than $1 billion.

Represents Kemira in connection with development of its patent portfolio relating to chemical products for use in oil, gas and mining.

Represents Duke University in U.S. and international prosecution of its patent portfolio relating to nucleic acid aptamers targeting therapeutically important proteins, including coagulation proteins.

Represents The Coca-Cola Company in development of its patent portfolio relating to bio-based plastics, including bio-polyethylene terephthalate, or PET, and polyethylene furanoate, or PEF, including PlantBottle.

Represented Regado Biosciences (Tobira Therapeutics) as IP counsel in multiple transactions, including venture capital financings, geographical-based licensing and its initial public offering.

Represented The Coca-Cola Company in negotiating and drafting licensing, development and commercialization agreements relating to novel sweeteners and bio-plastics.

Represented a privately held ophthalmology company in connection with a partial acquisition by a multi-national ophthalmology company.

Represented Nivalis Therapeutics, Inc., as IP counsel in connection with its initial public offering.

Represents Aceras Bio, a healthcare investment firm, in due diligence directed to formation and funding of life sciences companies.

Represents GeoVax, Inc., in client counseling and development of its patent portfolio relating to vaccines for HIV and other viral disorders.

Represented EndoChoice, a platform GI company, as IP counsel in connection with its initial public offering.

Represented a multinational conglomerate in monetization of a patent portfolio directed to mass spectrometric imaging by MALDI-TOF.

Credentials

B.S., Wake Forest University

J.D., University of Pittsburgh

Georgia

Strategy 300: The World's Leading IP Strategists


Intellectual Asset Management, 2016, 2015

Patent 1000: The World's Leading Patent Professionals


Intellectual Asset Management, 2016, 2015